製品番号: HY-B0172

リトコール酸

(別名: Lithocholic acid; 3α-Hydroxy-5β-cholanic acid)

21 Cited Publications

カスタマーレビュー

Based on 21 publication(s) in Google Scholar

Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a FXR antagonist and a PXR/SXR agonist.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.96%
CAS 番号: 434-13-9
分子式: C₂₄H₄₀O₃
分子量:376.57

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Lithocholic acid 構造式

CAS 番号: 434-13-9

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- Induced Disease Models
化学情報
Publications (21)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a FXR antagonist and a PXR/SXR agonist^[1]^[2]^[3]^[4]^[5].

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

Endogenous Metabolite アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>200 μM Compound: LCA	Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
Caco-2	IC₅₀	56 μM Compound: LCA	Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24332653]
CHO	EC₅₀	0.58 μM Compound: 6, LCA	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
CHO	EC₅₀	5.6 μM Compound: LCA	Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay	[PMID: 19911773]
COS-1	EC₅₀	20 μM Compound: 6, LCA	Agonist activity at human FXR expressed in COS1 cells by luciferase assay Agonist activity at human FXR expressed in COS1 cells by luciferase assay	[PMID: 18307294]
COS-1	EC₅₀	6.7 μM Compound: LCA	Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay	[PMID: 19911773]
DLD-1	IC₅₀	173.1 μM Compound: LCA	Cytotoxicity against human DLD1 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human DLD1 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25685308]
Erythrocyte	IC₅₀	0.009 mg/mL Compound: L	Hemolytic activity in human erythrocytes assessed as release of hemoglobin after 60 mins Hemolytic activity in human erythrocytes assessed as release of hemoglobin after 60 mins	[PMID: 24461290]
HCT-116	IC₅₀	>200 μM Compound: LCA	Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
HCT-116	IC₅₀	81.1 μM Compound: LCA	Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25685308]
HCT-8	IC₅₀	97.4 μM Compound: LCA	Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25685308]
HEK293	EC₅₀	0.68 μM Compound: 1, LCA	Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay	[PMID: 25735208]
HEK-293T	EC₅₀	2.14 μM Compound: LCA	Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HEK-293T	IC₅₀	46.7 μM Compound: LCA	Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HepG2	EC₅₀	50 μM Compound: LCA	Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay	[PMID: 27652492]
HepG2	EC₅₀	50 μM Compound: LCA	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay	[PMID: 27652492]
HET-1A	CC₅₀	25 μM Compound: 35, LCA	Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 20713311]
HT-1080	IC₅₀	23 μM Compound: LCA	Cytotoxicity against human HT1080 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HT1080 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24332653]
HT-29	IC₅₀	>200 μM Compound: LCA	Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
Huh-7	IC₅₀	>200 μM Compound: LCA	Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
LoVo	IC₅₀	>200 μM Compound: LCA	Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
MGC-803	IC₅₀	>200 μM Compound: LCA	Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
NCI-H716	EC₅₀	5 μM Compound: LCA	Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis	[PMID: 24900463]
PC-3	IC₅₀	50 μM Compound: 1, LCA	Antagonist activity at EphA2 in human PC3 cells assessed as inhibition of ephrin-A1-Fc-stimulated EphA2 phosphorylation pretreated for 20 mins by sandwich ELISA Antagonist activity at EphA2 in human PC3 cells assessed as inhibition of ephrin-A1-Fc-stimulated EphA2 phosphorylation pretreated for 20 mins by sandwich ELISA	[PMID: 23489211]
RKO	IC₅₀	>200 μM Compound: LCA	Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
SK-HEP1	IC₅₀	>200 μM Compound: LCA	Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
SW480	IC₅₀	>200 μM Compound: LCA	Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]

体外実験

Lithocholic acid inhibits CDCA- and GW4064-induced FXR activation with an IC₅₀of 0.7 and 1.4 μM, respectively^[5].
Lithocholic acid (10-30 μM, 24 h) inhibits the 100 nM GW4064 induced BSEP expression in HepG2 cells^[5].
Lithocholic acid (0-500 μM) dose-dependently inhibits the proliferation of neuroblastoma cells (BE(2)-m17, SK-n-SH, SK-n-MCIXC and Lan-1)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Animal Model:

Male mice (C57BL/6)^[4].
Dosage:

0.6% LCA-supplement diet, with the AIN93G diet as a control
Administration:

in diet, for 6 days
Result:

Induced liver injury.
Activated TGFβ-SMAD3 signaling.
Increased serum ALP activities.

Animal Model:

Male mice (C57BL/6)^[2].
Dosage:

125 mg/kg, dissolved in corn oil
Administration:

i.p., twice a day for four days
Result:

Induced liver injury, generated necrosis and neutrophilic-granulocytic infiltrate (H&E staining).
Increased AST, ALT and ALP level.

Induced Disease Models

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Lithocholic acid (LCA) can be used to induce cholestasis models^[6]^[7].

Induction of cholestasis^[6]^[7]

Background

LCA has certain toxicity to hepatocytes, which can change bile secretion through its osmotic effect and cause cholestasis by changing the cell membrane components of hepatocytes that are rich in bile duct membranes.

Specific Modeling Methods

Rat: Wistar • male • 250 ~ 300 g (period: 1 h)
Administration: 0.2 μmol/100 g • iv • killed after 1 h
Mice: ICR • male • 5-7-week-old (period: 3 days)
Administration: 150 mg/kg • po • 2 times a day for 5 times

Note

(1) LCA (i.v.) is taken up in 7.5% bovine serum albumin and 0.45% saline.
(2) LCA (p.o.) is taken up in corn oil. The animals were sacrificed 12 h following the 5th treatment. The blood samples (50 μl) can be collected by tail bleeding at 0, 12, 24 and 36 h following the 1st dose.

Modeling Indicators

Histological changes: There was a significant increase in bile flow shortly after LCA injection, after which bile flow decreased significantly. Pathological changes can be observed in liver tissue, including liver necrosis and diffuse vacuoles.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 434-13-9
性状 Solid
分子量 376.57
分子式 C₂₄H₄₀O₃
Color White to off-white
SMILES

C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(O)=O)([H])[C@@]3([H])[C@]([C@@]4([C@](C[C@H](O)CC4)([H])CC3)C)([H])CC1
別名

Lithocholic acid; 3α-Hydroxy-5β-cholanic acid
Structure Classification
- Steroids
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (21)

All RT-PCRHistological Imaging/StainingIn Vivo Efficacy StudyIHCBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227
Imeta

2026 Feb 19.
Cell Res

Virus-induced accumulation of intracellular bile acids activates the TGR5-β-arrestin-SRC axis to enable innate antiviral immunity. [Abstract]

2019 Mar;29(3):193-205. PMID: 30651583

Lithocholic acid purchased from MedChemExpress. Usage Cited in: Cell Res. 2019 Mar;29(3):193-205. [Abstract]

Effects of bile acids (BAs) on virus-induced transcription of antiviral genes. Raw264.7 cells were infected with HSV-1 or SeV for 30 min and treated with Lithocholic acid (LCA) (0.1 mM), Chenodeoxycholic Acid (CDCA) (0.1 mM) or Deoxycholic acid (DCA) (0.1 mM) for 6 h before qPCR analysis of the indicated mRNA levels.

Lithocholic acid purchased from MedChemExpress. Usage Cited in: Cell Res. 2019 Mar;29(3):193-205. [Abstract]

Examination of intracellular bile acids (BA) levels after cells were treated with exogenous BAs. Raw264.7 cells were infected with HSV-1 or SeV for 30 min and treated with Lithocholic acid (LCA) (0.1 mM), Chenodeoxycholic Acid (CDCA) (0.1 mM) or Deoxycholic acid (DCA) (0.1 mM) for 6 h before BA assays were performed.
Cell Host Microbe

Veillonella intestinal colonization promotes C. difficile infection in Crohn's disease. [Abstract]

2025 Aug 19:S1931-3128(25)00291-4. PMID: 40848719
Cell Host Microbe

A gut microbiota-bile acid axis promotes intestinal homeostasis upon aspirin-mediated damage. [Abstract]

2024 Feb 14;32(2):191-208.e9. PMID: 38237593
Adv Sci (Weinh)

Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis. [Abstract]

2025 Mar;12(12):e2411719. PMID: 39899681

Lithocholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(12):e2411719. [Abstract]

The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.
Pharmacol Res

Host ALDH2 deficiency aggravates nonalcoholic steatohepatitis through gut-liver axis. [Abstract]

2023 Oct:196:106902. PMID: 37657657

Lithocholic acid purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2023 Oct:196:106902. [Abstract]

LCA supplementation ameliorated MCD-induced NASH aggravated by ALDH2 deficiency. Representative photomicrographs of liver sections stained with H&E or Oil-red O (scale bar, 100 μm); the NAS score and oil red O-positive area were analysed and quantified (n = 8).
J Transl Med

Conjugated bile acids alleviate acute pancreatitis through inhibition of TGR5 and NLRP3 mediated inflammation. [Abstract]

2024 Dec 20;22(1):1124. PMID: 39707318
J Transl Med

Quantitative proteomic and phosphoproteomic analysis reveal the relationship between mitochondrial dysfunction and cytoskeletal remodeling in hiPSC-CMs deficient in PINK1. [Abstract]

2023 Aug 30;21(1):581. PMID: 37649075
Cell Prolif

Suppression of the gut microbiota-bile acid-FGF19 axis in patients with atrial fibrillation. [Abstract]

2023 Nov;56(11):e13488. PMID: 37186335
Br J Pharmacol

Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity. [Abstract]

2019 Jul;176(13):2162-2178. PMID: 30875096
J Invest Dermatol

Bile Acids Improve Psoriasiform Dermatitis through Inhibition of IL-17A Expression and CCL20-CCR6-Mediated Trafficking of T Cells. [Abstract]

2022 May;142(5):1381-1390.e11. PMID: 34808237

Lithocholic acid purchased from MedChemExpress. Usage Cited in: J Invest Dermatol. 2022 May;142(5):1381-1390.e11. [Abstract]

(a) Schematic illustration of experimental protocols. Mice were administered i.v. PBS vehicle or LCA (Lithocholic acid, ) at a dose of 4 mg/kg/per day every other day beginning the following day after MC was delivered. (b) Percentage of baseline body weight, (c) representative photographs, (d) time course of ear thickness.

Lithocholic acid purchased from MedChemExpress. Usage Cited in: J Invest Dermatol. 2022 May;142(5):1381-1390.e11. [Abstract]

Wild-type C57BL/6 mice were administered i.v. PBS vehicle or LCA (Lithocholic acid ) at a dose of 4 mg/kg/per day every other day beginning the following day after MC was delivered.Image of H&E section (up), representative images of Ki-67 immunohistochemistry (bottom).
Food Funct

Apigenin protects mice against 3,5-diethoxycarbonyl-1,4-dihydrocollidine-induced cholestasis. [Abstract]

2021 Mar 15;12(5):2323-2334. PMID: 33620063
Cells

PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells. [Abstract]

2026 Mar 5;15(5):473. PMID: 41827906
J Hypertens

Renal Farnesoid X Receptor improves high fructose-induced salt-sensitive hypertension in mice by inhibiting DNM3 to promote nitro oxide production. [Abstract]

2022 Aug 1;40(8):1577-1588. PMID: 35792095
Sci Rep

PPARα activation protects against cholestatic liver injury. [Abstract]

2017 Aug 30;7(1):9967. PMID: 28855630
Cell Signal

2026 Mar 6.
Aquaculture

2023 Sep 18, 740123.
Microb Pathog

Lithocholic acid exerts antiviral activity against porcine epidemic diarrhea virus by enhancing TGR5-mediated type III interferon production. [Abstract]

2026 Jan:210:108187. PMID: 41242567
Food Chem Toxicol

Metabolomic analysis of cholestatic liver damage in mice. [Abstract]

2018 Oct:120:253-260. PMID: 30009888
bioRxiv

2026 Jun 19.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (265.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 10 mg/mL (26.56 mM; ultrasonic and warming and heat to 60°C)

H₂O : 0.99 mg/mL (2.63 mM; ultrasonic and warming and adjust pH to 11 with NaOH and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6555 mL

13.2777 mL

26.5555 mL

5 mM

0.5311 mL

2.6555 mL

5.3111 mL

10 mM

0.2656 mL

1.3278 mL

2.6555 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (2.66 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 4

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (2.66 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 5

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 1 mg/mL (2.66 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (280 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Jenkins, D.J., et al., Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol. N Engl J Med, 1993. 329(1): p. 21-6. [Content Brief]

[2]. Yang R, et al. Metabolomic analysis of cholestatic liver damage in mice. Food Chem Toxicol. 2018 Jul 14;120:253-260. [Content Brief]

[3]. Goldberg, A.A., et al., Lithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cells. Oncotarget, 2011. 2(10): p. 761-82. [Content Brief]

[4]. Matsubara, T., et al., TGF-beta-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury. J Lipid Res, 2012. 53(12): p. 2698-707. [Content Brief]

[5]. Yu J, et al. Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / Ethanol / DMSO	1 mM	2.6555 mL	13.2777 mL	26.5555 mL	66.3887 mL
Ethanol / DMSO	5 mM	0.5311 mL	2.6555 mL	5.3111 mL	13.2777 mL
	10 mM	0.2656 mL	1.3278 mL	2.6555 mL	6.6389 mL
	15 mM	0.1770 mL	0.8852 mL	1.7704 mL	4.4259 mL
	20 mM	0.1328 mL	0.6639 mL	1.3278 mL	3.3194 mL
	25 mM	0.1062 mL	0.5311 mL	1.0622 mL	2.6555 mL
DMSO	30 mM	0.0885 mL	0.4426 mL	0.8852 mL	2.2130 mL
	40 mM	0.0664 mL	0.3319 mL	0.6639 mL	1.6597 mL
	50 mM	0.0531 mL	0.2656 mL	0.5311 mL	1.3278 mL
	60 mM	0.0443 mL	0.2213 mL	0.4426 mL	1.1065 mL
	80 mM	0.0332 mL	0.1660 mL	0.3319 mL	0.8299 mL
	100 mM	0.0266 mL	0.1328 mL	0.2656 mL	0.6639 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Lithocholic acid

21 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

リトコール酸

Lipid Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Anti-Obesity Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Human Metabolite Library

Nuclear Receptor Compound Library

Anti-Aging Natural Product Library

Metabolic Enzyme Compound Library

Animal-Sourced Natural Product Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Fatty Acids Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Bile Acids Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Lipid Metabolite Compound Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Human Endogenous Metabolite Compound Library

Drug Repurposing Compound Library

MedChemExpress（MCE）の使用を引用している文献 Lithocholic acid

Endogenous Metabolite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (21)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Lithocholic acid 関連分類

HY-B0172 関連分類